Related content

Phase II randomized trial of weekly and every-3-week ixabepilone in metastatic breast cancer patients

By Smith John   Vukelja Svetislava   Rabe Amy   Wentworth-Hartung Nicole   Koutrelakos Nicholas   Shao Spencer   Whittaker Thomas   Wang Yunfei   Asmar Lina   McDowell Diane   Mukhopadhyay Pralay   O’Shaughnessy Joyce  

Breast Cancer Research and Treatment, Vol. 142, Iss. 2, 2013-11 ,pp. : 381-388

Springer Publishing Company

Access to resources Recommend Favorite

Ixabepilone for the treatment of taxane-refractory breast cancer

By Moulder Stacy L  

Future Oncology, Vol. 4, Iss. 3, 2008-06 ,pp. : 333-340

Future Medicine

Access to resources Recommend Favorite

Ixabepilone plus capecitabine with capecitabine alone for metastatic breast cancer

By Li Lun   Li Jiang   Yang Kehu   Tian Jinhui   Sun Tiantian   Jia Wenqin   Zhang Peng   Yi Kang  

Future Oncology, Vol. 6, Iss. 2, 2010-02 ,pp. : 201-207

Future Medicine

Access to resources Recommend Favorite

Hypertriglyceridemia in patients with metastatic breast cancer and treatment with capecitabine

By Geva Shahar   Lazarev Irena   Geffen David Barry   Ariad Samuel  

Journal of Chemotherapy, Vol. 25, Iss. 3, 2013-06 ,pp. : 176-180

Maney Publishing

Access to resources Recommend Favorite

A Phase II Multicenter Study of Two Different Dosages of Pemetrexed Given in Combination With Cyclophosphamide as First-Line Treatment in Patients With Locally Advanced or Metastatic Breast Cancer

By Dittrich Christian   Solska Ewa   Manikhas Alexey   Eniu Alexandru   Tjulandin Sergei   Anghel Rodica   Musib Luna   Frimodt-Moller Bente   Liu Yushan   Krejcy Kurt   Láng István  

Cancer Investigation, Vol. 30, Iss. 4, 2012-04 ,pp. : 309-316

Informa Healthcare

Access to resources Recommend Favorite